Lanny Breuer, the head of the Justice Department’s Criminal Division, told drug-company executives last year that investigating foreign bribery in the industry would be one of his priorities over the next several years.
Looks like he’s staying true to his word.
On Tuesday, the WSJ’s Michael Rothfeld reports that federal investigators are looking at ways that drug makers could be paying bribes overseas to boost sales and speed approvals.
Big companies—including Merck, AstraZeneca, Bristol-Myers Squibb and GlaxoSmithKline —in recent months have disclosed they are being investigated for possible violations of the Foreign Corrupt Practices Act, the now ubiquitous 1977 law that makes it illegal for companies whose stock is traded in the U.S. to bribe government officials in other countries to get business.
The companies said they are cooperating with the government, with several adding that the investigation is industry-wide and broader than their companies specifically. So far, none of the companies has been accused of wrongdoing, and the investigation ultimately may not result in charges.
The investigation is targeting transactions in Brazil, China, Germany, Italy, Poland, Russia and Saudi Arabia, people familiar with the matter said.